S&P DJI Announces September 2025 Quarterly Rebalance
Filed with ASX · · 7 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- Preliminary Final Report
- Clarity successfully completes $203 million institutional pl
- Co-PSMA trial: Recruitment successfully completed
- Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
- Clarity enters a Commercial Manufacturing Agreement
Later from Clarity Pharmaceuticals
- Co-PSMA trial achieves primary endpoint
- Clarity signs copper-67 Supply Agreement with Nusano
- AGM MD Presentation
- Positive guidance from the US FDA on Cu-64 SARTATE Phase III
- Co-PSMA abstract accepted for oral presentation at EAU
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals